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The CardioMEMS Champion Heart Failure Monitoring System (CardioMEMS, Atlanta, Georgia) is a permanently
implantable pressure measurement system designed to wirelessly measure and monitor pulmonary artery (PA)
pressure and heart rate in heart failure (HF) patients to guide ambulatory HF management and to reduce HF
hospital stays. On December 8, 2011, the Food and Drug Administration (FDA) Circulatory System Device Panel
reviewed the CardioMEMS Champion HF Monitoring System premarket approval (PMA) application. The majority
of Panel members agreed that that the discussed monitoring system is safe for use in the indicated patient pop-
ulation. However, new information reported by the FDA with regard to preferential support in management of
patients in the treatment group raised concerns among the Panel members with regard to potential bias in ana-
lyzing the efficacy of the device itself. Additionally, Panel members raised concerns with regard to the efficacy of
the device in certain patient subpopulations. Hence, most Panel members decided that there was not reason-
able assurance that the discussed monitoring system is effective. This summary aims to describe the discus-
sions and recommendations made during this meeting. (J Am Coll Cardiol 2013;61:1571–6) © 2013 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1035The CardioMEMS Champion Heart Failure Monitoring
System (CardioMEMS, Atlanta, Georgia) is a permanently
implantable pressure measurement system designed to pro-
vide daily pulmonary artery (PA) pressure measurements in
an ambulatory setting and thus help guide heart failure (HF)
management in an outpatient setting to reduce HF hospital
stays. The system consists of an implantable sensor/
monitor, which is a battery-free capacitive pressure sensor
permanently implanted in the PA; a transvenous delivery
system designed to deploy the implantable sensor in the
distal PA; and the Champion Electronics System (Car-
dioMEMS), which acquires and processes signals from the
implantable sensor/monitor and transfers PA pressure mea-
surements to a secure database accessible by the treating
physician.
On December 8, 2011, the Food and Drug Administra-
tion (FDA) Circulatory System Devices Panel reviewed the
CardioMEMS Champion HF Monitoring System premar-
ket approval (PMA) application. Meeting materials can be
accessed at the FDA website (1).
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accepted August 7, 2012.The PMA application was primarily based on data from
the pivotal, prospective, multi-centered, randomized,
single-blinded CHAMPION (CardioMEMS Heart Sensor
Allows Monitoring of Pressure to Improve Outcomes in
NYHA Class III Heart Failure Patients) trial, which was
published in the Lancet earlier this year (2), which consisted
of patients in New York Heart Association (NYHA)
functional class III HF with a previous hospital stay within
the last year; 270 patients were randomized to PA pressure-
guided treatment of HF compared with 280 in the control
arm. Of note, all patients underwent implantation of the
device, but no PA pressure measurements were performed
in the control group.
The following is a summary of the discussions and
recommendations made during the Circulatory System
Devices Advisory Panel meeting.
Efficacy Controversy
On behalf of the trial sponsor, Dr. William Abraham, the
Principal Investigator of the CHAMPION trial, presented
the trial design and the major clinical outcomes of the
pivotal trial. According to the published trial results in terms
of primary efficacy, there was a statistically significant risk
reduction from 0.44 to 0.32 in heart failure-related (HFR)
hospital stays/patient/6 months, with a relative risk reduc-
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reduction of 0.12 HFR hospital
stay events, demonstrating the
superiority of the treatment arm
(p  0.0002). The supplemen-
tary efficacy endpoint demonstrated
continuous, significant, risk reduc-
tion in HFR hospital stays from
0.73 to 0.46 (p  0.0001), with a
37% relative risk reduction over
the full study duration (Fig. 1).
The time to first event analysis,
combining death from any cause
and HFR hospital stay for the
full study duration, significantly
favored the treatment group with
hazard ratio of 0.73 (95% confidence interval: 0.57 to 0.94,
 0.015) (Fig. 2).
Although the pre-specified statistical model used by the
ponsor showed a highly significant treatment effect (p 
0.0002), the analysis did not take into account the greater
than expected variability in the CHAMPION dataset with
regard to the primary endpoint of number of hospital stays
based on that model (i.e., the observed variance was larger
than the observed mean). Moreover, many patients did not
require hospital stay during the follow-up period. If this
over-dispersion was not appropriately accounted for, the
estimation of standard errors would be too small, thereby
leading to smaller p values. As presented by Dr. Yonghong
Gao, FDA statistician, alternative statistical models were
used to correct for this over-dispersion and indicate that,
under certain circumstances, the significant effect of the
CardioMEMS Champion HF monitoring system on the
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Figure 1 Cumulative HF Hospital Stays
Cumulative heart failure (HF) hospital stays of the treatment and control
groups throughout the duration of the study. RRR  relative risk reduction.primary endpoint of the trial disappears. Hence, the FDA
concluded that the statistical methods used by the Sponsor
for analysis of the primary efficacy endpoint were not robust
and indicated that the potential benefit of the device is so
marginal that as few as 13 more HFR hospital stays (from
84 to 97) in the treatment arm would render the results as
no longer statistically significant. For an alternative boot-
strap model, even 2 additional hospital stays in the treat-
ment arm converted the p value to exceed 0.1.
Trial Conduct Issues
Auditing performed by the FDA Division of Bioresearch
Monitoring after completion of patient enrollment and after
most of the follow-up period identified evidence that the
Sponsor and national Principal Investigators, who were not
blinded to the randomization assignment, routinely con-
tacted investigational sites and made specific therapeutic
recommendations for some treatment group study subjects
via electronic communication. According to Drs. Randall
Brockman and Gregory Campbell of the FDA, such com-
munications included but were not necessarily limited to
titration of medication doses, addition or discontinuation of
medications, recommendations for outpatient intravenous
medication administration, addition of medications that
were not in the protocol and sleep study evaluations that
were not included in the protocol. These “auxiliary inter-
ventions” occurred only in the treatment arm patients.
According to the FDA, this mode of preferential com-
munication introduces a significant bias to the study and
ultimately disallows objective assessment of the inherent
effect of the CardioMEMS Champion HF monitoring
Figure 2 Freedom From HF Hospital Stay or Death
Freedom from heart failure (HF) hospital stay or death of the treatment
and control groups throughout the duration of the study. HR  hazard ratio.device in the management of HF patients.
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April 16, 2013:1571–6 FDA Advisory Panel Meeting on the CardioMEMS SystemIncorporating the data as presented by the FDA and the
Sponsor, it seemed that although both sides conjointly
designed and prospectively agreed on a specific protocol for
the CHAMPION trial, there were differences in the inter-
pretation of certain portions (i.e., Appendix E of the
CHAMPION trial protocol; see FDA executive summary—
Addendum) (3). The approved protocol allowed the Spon-
sor to review the PA pressure readings and to alert investi-
gators if the pressure readings were beyond set alert limits.
The Investigators (or Designees) were to manage the
enrolled subjects and make medication changes according to
the recommendations in Appendix E. However, the level of
interaction between the Sponsor and Clinical Investigators
on specific treatment group subjects was inconsistent with
the expectations of the FDA and was unbalanced with
respect to the control group.
In response to the FDA claims, Dr. William Abraham,
Principal Investigator of the CHAMPION Trial, presented
data to show that the absolute number of those emails was
low (Fig. 3). He showed that these communications did not
significantly affect rates of medication changes/patient/
month or affect the outcome of HFR hospital stays when
the treatment group was stratified into those who received
emails and those who did not (Table 1). The Sponsor also
presented data showing that even after the un-blinded
period with no further follow-up emails, there was no
significant change in patient outcome in the treatment
Figure 3 Number of Pressure Readings,
Reviews, and Recommendation Emails
Total number of pulmonary artery (PA) pressure readings taken, the total num-
ber of reviews performed by investigator log-ins, and the number of recommen-
dation emails sent to investigators in 6 months for the treatment group
patients.
Association Between Emails Received and Outcome of HFR HospitTable 1 Association Between Emails Received and Outcome o
Up to 6 Months
(n  270)
Treatment patients Received emails
n  151
Received no emails
n  119
HFR hospital stay rate 0.36/6 months 0.26/6 monthsHFR  heart failure-related.group (Table 2). Finally, the Sponsor claimed that the
proportion of patients receiving such emails was very small
and even in a worst case scenario it would have affected very
few patient outcomes.
The FDA was not reassured by the presented data,
because there was reasonable doubt whether the FDA had
access to all of the questionable email communications and
possible telephone conversations. Furthermore, even if the
outcomes of only a few patients in the treatment group were
affected by these extra-curricular conversations, the results
of the entire study might have depicted an insignificant
difference between the 2 study groups.
The Advisory Panel members had an extensive discussion
with regard to the conduct of the CHAMPION trial and to
the validity of the efficacy results. The consensus of the
Advisory Panel was that a substantial bias was introduced
into the study results, due to the preferential assistance in
the management of the treatment arm patients. Moreover,
it was difficult to distinguish the inherent benefits of the
device versus the effects of the device combined with HF
expert management guidance. Unfortunately, these auxiliary
activities were done in a manner that precluded any at-
tempts to exclude the involved patients and any attempts to
perform post hoc analysis to evaluate a subgroup of patients
who did not have such interventions. An additional concern
to the Panel was that these communications were identified
at a very late stage in the trial, at which point it was too late
to reconcile them to salvage the study.
Subgroup Analysis
An additional area of disagreement between the FDA and
the Sponsor was the clinical efficacy of the Champion HF
Monitoring System for certain subpopulations. Dr. Yong-
hong Gao of the FDA presented a post hoc analysis of HFR
hospital stay rates according to sex (Table 3). The data
indicated significant interaction between sex and treatment,
suggesting that the device has differential treatment effects
on men and women. The intervention in the treatment arm
reduced the hospital stay rate for men, but there was a
nonstatistically significant increase for women at the
6-month follow-up period. When the data were analyzed
over the entire study duration, treatment effect was again
shown in men but not in women (Fig. 4).
In response, the Sponsor highlighted that the small
number of events (14 HFR hospital stays among 75 pa-
tients) in the female control group might result in statistical
artifacts and prevents drawing meaningful conclusions. The
ysHospital Stays
After 6 Months to Unblinding
(n  244)
After Unblinding
(n  383)
Received emails
n  133
Received no emails
n  111
Received no emails
n  383
0.32/yr 0.40/yr 0.47/yral Staf HFR
atients
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in deaths in the female control group (7 control deaths vs. 3
treatment deaths, hazard ratio  0.41, p  0.187), the
women in the control group most likely to have HF hospital
stays had a reduced duration in the study and reduced
contribution to the primary endpoint of HFR hospital stays.
When both mortality and HFR hospital stays were consid-
ered together in the endpoint, the apparent disparity in the
results for women disappeared. In the univariable analysis
presented by the Sponsor, the apparent interaction between
treatment and sex was explained by other risk factors present
at baseline; this interaction was no longer statistically
significant (p  0.940) after the multivariable adjustment.
During the Advisory Panel deliberations, most Panel
members agreed that the small number of events in women
were not powered to look at differences in sex, but there was
some evidence of sex and treatment interaction. The Panel
concluded that the data were not sufficient for assessing the
impact of the system on women.
Another subgroup analysis discussed during the Panel
meeting was HF patients with preserved left ventricular
ejection fraction (LVEF) (Fig. 5). The Sponsor presented
data that indicated that patients with preserved LVEF had
lower hospital stay rates in the treatment group as compared
with the control group (0.18 vs. 0.33 HFR hospital stay/
patient/6 months; p 0.001).
The Panel agreed that these results were significant across
the subgroups of reduced and preserved LVEF, and this
trial represented 1 of the first successful management
strategies to reduce hospital stay risks for HF patients with
preserved LVEF.
Safety Assessment
In the CHAMPION trial, primary safety endpoints were
based on 550 randomized and 25 consented nonrandom-
HFR Hospital Stay Rates of All PatientsDuring Full Study Duration and After UnblindingTable 2 HFR Hospital Stay R es of All PatiDuring Full Study Duration and Afte
Full Study Durat
(n  550)
All patients Treatment
n  270
HFR hospital stay rate/yr 0.46
Heart failure-related (HFR) hospital stay rates (events/person) of all p
HFR Hospital Stay Rate at 6 Months Stratified bTable 3 HFR Hospital Stay Rate at 6 Month
Treatment
(n  270)
Male (n  399) 60 events
n  194 patients
HFR hospital stay rate: 0.32
Female (n  151) 24 events
76 patients
HFR hospital stay rate: 0.32Heart failure-related (HFR) hospital stay rate (events/person) at 6 months strized, not implanted patients. Because all randomized pa-
tients had implantation of the pressure sensor and there was
no real control group for safety, the comparison of safety
endpoints with pre-specified Objective Performance Crite-
ria (OPC) was performed. These OPC were based upon the
complication and failure rates for other HF monitoring
devices and similar to OPC accepted by the FDA. The
Panel agreed with the FDA that the primary safety endpoint
seemed to have been met for freedom from device/system-
related complications at 6 months (98.6%, lower 95%
confidence limit  97.3%, compared with pre-specified
OPC of 80%). Freedom from sensor failure at 6 months
(100%, lower 95% confidence limit  99.3%, compared
with pre-specified OPC of 90%) was also met.
Panel Recommendations
The Panel was asked to vote on 3 questions with respect to
the approvability of the CardioMEMS Champion HF
Monitoring System. The Panel voted 9 to 1 that there is
reasonable assurance that the CardioMEMS Champion HF
Monitoring System is safe for use in patients with NYHA
functional class III HF who meet the criteria specified in the
proposed indication. One Panel member felt that, although
the implantation of the device was safe, there had been
conflicting data on women, which represented part of the
intended population, and he could not be reasonably assured
that it was safe for use in that group. Furthermore, the
application of the device in making decisions on PA
pressures without the entire support system might poten-
tially cause harm.
The Panel voted 7 to 3 against the statement that there is
reasonable assurance that the CardioMEMS Champion HF
Monitoring System is effective for use in patients with Class
III HF who meet the criteria specified in the proposed
indication. Most Panel members who voted negatively on
linding
After Unblinding
(n  383)
l
0
Former treatment
n  186
Former control
n  197
0.46 0.49
during the full study duration and after unblinding.
xatified by Sex
Control
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hospital stay rate: 0.53
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effect seen in the trial was a combination of device and
support mechanism; there was no way to tease out the
treatment effect of each; and major elements in the support
system will not be applicable in the general population. One
Panel member who voted against also mentioned the
conundrum of the treatment effect on women. The Panel
members who voted “for” considered the entirety of the
treatment effect and voiced hope that this support system
could be replicated by the Sponsor outside of the trial
setting.
The Panel voted 6 to 4 against the statement that the
benefits of the CardioMEMS Champion HF Monitoring
Figure 4 HRs of Sex Subgroups for HF Hospital Stays
Hazard ratios (HRs) according to sex subgroups for HF hospital stays throughout t
Figure 5 HF Hospital Stays by EF
This figure shows the heart failure (HF) hospital stay rates according to base-
line preserved and reduced left ventricular ejection fraction (EF) at 6 months.
RRR  relative risk reduction.tSystem outweigh the risks for use in patients who meet the
criteria specified in the proposed indication.
Expedited Publication Versus Lingering Approval
In this FDA advisory panel meeting, most of the discussion
focused on the study design and conduct and how these
impacted the results of the CHAMPION pivotal trial.
Interestingly, the results of the CHAMPION trial were
published earlier this year in the Lancet and were accompa-
ied by a positive editorial piece suggesting that, on the
asis of the trial results, strong consideration should be
iven to device implantation in Class III HF patients (2,4).
owever, auditing performed by the FDA uncovered cer-
ain conduct issues that challenged the validity of the
ublished results. This type of auditing and the availability
f the FDA advisory panel are obviously beyond the scope
nd resources of any specific journal. Although medical
ournals are focusing on publishing late-breaking trials
xpeditiously, the regulatory agencies are charged to con-
uct full investigations into the accuracy of the results and
he integrity of its conduct. These are usually lingering, and
he FDA is often criticized for slowing the approval process.
n the case of the CHAMPION trial, due diligence by the
DA uncovered a vastly different trial conduct and hence a
ifferent trial interpretation from that contained in the
ancet. This has led to a disparity between praised study
esults published in a leading medical journal and contra-
ictory interpretation by a respected panel of experts who
dvised the FDA that there is lack of reasonable assurance
his technology is effective in reduction for the need of
epeat hospital stay in patients with HF.
Although the CardioMEMS technology might be valu-
ble for monitoring patients with HF, it might now take a
ew study to prove beyond a reasonable doubt the effective-
ess of the technology and, if required, as pre-market rather
ation of the study. CI  confidence interval.he durhan post-market. This might further delay the approval of
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for close and early monitoring of pivotal clinical trials. Had
the FDA identified its findings in the early phase of the
study, the deficiencies could have been corrected and the
efficacy controversy could have been eliminated. Thus it is
reasonable to consider a new FDA policy of performing a
preliminary audit early on after initiation of Investigational
Device Exemption clinical trials, so that such issues as the 1
encountered in this PMA submission would be identified
and corrected in a timely fashion without jeopardizing the
entire trial.
Conclusions
This FDA Circulatory System Devices Panel meeting on
the CardioMEMS Champion Heart failure monitoring
system was unusual. The Panel commended the Sponsor on
this innovative technology and its potential for adding value
to HF management. The FDA took a very unusual step in
devoting a substantial portion of the discussion to challenge
the trial conduct and, hence, the validity of the data
presented. Finally, the Panel decided that the inherent
efficacy of the device could not be determined by the results
presented to the Panel. It will be interesting to follow what
further steps the FDA and the Sponsor will take to bringthis promising technology to a resolution with regard to its
future clinical use.
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